Corcept Therapeutics [CORT] vs Regeneron [REGN] Detailed Stock Comparison
Corcept Therapeutics
NASDAQ
Loading...
Regeneron
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Corcept Therapeutics wins in 7 metrics, Regeneron wins in 12 metrics, with 0 ties. Regeneron appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Corcept Therapeutics | Regeneron | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 64.06 | 14.62 | Regeneron |
| Price-to-Book Ratio | 11.88 | 2.02 | Regeneron |
| Debt-to-Equity Ratio | 1.04 | 9.04 | Corcept Therapeutics |
| PEG Ratio | -21.78 | 12.81 | Corcept Therapeutics |
| EV/EBITDA | 70.40 | 12.41 | Regeneron |
| Profit Margin (TTM) | 18.67% | 31.37% | Regeneron |
| Operating Margin (TTM) | 13.72% | 29.64% | Regeneron |
| EBITDA Margin (TTM) | 13.72% | 29.64% | Regeneron |
| Return on Equity | 21.70% | 15.34% | Corcept Therapeutics |
| Return on Assets (TTM) | 8.36% | 6.66% | Corcept Therapeutics |
| Free Cash Flow (TTM) | $195.90M | $3.54B | Regeneron |
| Dividend Yield | N/A | 0.46% | N/A |
| 1-Year Return | 111.22% | -50.78% | Corcept Therapeutics |
| Price-to-Sales Ratio (TTM) | 10.56 | 4.33 | Regeneron |
| Enterprise Value | $7.22B | $55.42B | Regeneron |
| EV/Revenue Ratio | 10.09 | 3.90 | Regeneron |
| Gross Profit Margin (TTM) | 98.23% | 85.58% | Corcept Therapeutics |
| Revenue per Share (TTM) | $7 | $133 | Regeneron |
| Earnings per Share (Diluted) | $1.12 | $39.70 | Regeneron |
| Beta (Stock Volatility) | 0.20 | 0.33 | Corcept Therapeutics |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Corcept Therapeutics vs Regeneron Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Corcept Therapeutics | -0.35% | -0.76% | 0.48% | -2.19% | -1.17% | 43.59% |
| Regeneron | 2.55% | 3.09% | 5.92% | -0.78% | -14.65% | -18.85% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Corcept Therapeutics | 111.22% | 159.31% | 455.34% | 1,470.02% | 2,382.70% | 1,202.18% |
| Regeneron | -50.78% | -6.14% | -4.14% | 10.10% | 2,431.23% | 6,768.76% |
Performance & Financial Health Analysis: Corcept Therapeutics vs Regeneron
| Metric | CORT | REGN |
|---|---|---|
| Market Information | ||
| Market Cap | $7.56B | $61.52B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 783,450 | 1,012,030 |
| 90 Day Avg. Volume | 886,380 | 965,153 |
| Last Close | $71.75 | $580.41 |
| 52 Week Range | $33.34 - $117.33 | $476.49 - $1,211.20 |
| % from 52W High | -38.85% | -52.08% |
| All-Time High | $117.33 (Mar 31, 2025) | $1,211.20 (Aug 26, 2024) |
| % from All-Time High | -38.85% | -52.08% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.19% | 0.04% |
| Quarterly Earnings Growth | -0.01% | -0.03% |
| Financial Health | ||
| Profit Margin (TTM) | 0.19% | 0.31% |
| Operating Margin (TTM) | 0.14% | 0.30% |
| Return on Equity (TTM) | 0.22% | 0.15% |
| Debt to Equity (MRQ) | 1.04 | 9.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.04 | $287.55 |
| Cash per Share (MRQ) | $3.25 | $72.04 |
| Operating Cash Flow (TTM) | $182.19M | $4.74B |
| Levered Free Cash Flow (TTM) | $166.88M | $2.85B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.46% |
| Last 12-Month Dividend | N/A | $2.64 |
Valuation & Enterprise Metrics Analysis: Corcept Therapeutics vs Regeneron
| Metric | CORT | REGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 64.06 | 14.62 |
| Forward P/E | 41.00 | 12.81 |
| PEG Ratio | -21.78 | 12.81 |
| Price to Sales (TTM) | 10.56 | 4.33 |
| Price to Book (MRQ) | 11.88 | 2.02 |
| Market Capitalization | ||
| Market Capitalization | $7.56B | $61.52B |
| Enterprise Value | $7.22B | $55.42B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 10.09 | 3.90 |
| Enterprise to EBITDA | 70.40 | 12.41 |
| Risk & Other Metrics | ||
| Beta | 0.20 | 0.33 |
| Book Value per Share (MRQ) | $6.04 | $287.55 |
Financial Statements Comparison: Corcept Therapeutics vs Regeneron
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CORT | REGN |
|---|---|---|
| Revenue/Sales | $157.21M | $3.03B |
| Cost of Goods Sold | $2.40M | $464.30M |
| Gross Profit | $154.81M | $2.56B |
| Research & Development | $60.74M | $1.34B |
| Operating Income (EBIT) | $3.42M | $591.70M |
| EBITDA | $3.88M | $900.90M |
| Pre-Tax Income | $9.62M | $905.00M |
| Income Tax | $-10.93M | $96.30M |
| Net Income (Profit) | $20.55M | $808.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CORT | REGN |
|---|---|---|
| Cash & Equivalents | $89.82M | $3.09B |
| Total Current Assets | $438.50M | $17.57B |
| Total Current Liabilities | $143.07M | $3.57B |
| Long-Term Debt | $5.85M | $2.70B |
| Total Shareholders Equity | $683.29M | $29.39B |
| Retained Earnings | $564.28M | $32.38B |
| Property, Plant & Equipment | $7.69M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CORT | REGN |
|---|---|---|
| Operating Cash Flow | $34.72M | $1.36B |
| Capital Expenditures | $-104,000 | N/A |
| Free Cash Flow | $5.02M | $773.60M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-1.05B |
Short Interest & Institutional Ownership Analysis
| Metric | CORT | REGN |
|---|---|---|
| Shares Short | 11.05M | 2.29M |
| Short Ratio | 12.13 | 2.55 |
| Short % of Float | 0.14% | 0.02% |
| Average Daily Volume (10 Day) | 783,450 | 1,012,030 |
| Average Daily Volume (90 Day) | 886,380 | 965,153 |
| Shares Outstanding | 105.11M | 109.62M |
| Float Shares | 87.04M | 97.91M |
| % Held by Insiders | 0.12% | 0.02% |
| % Held by Institutions | 0.76% | 0.91% |
Dividend Analysis & Yield Comparison: Corcept Therapeutics vs Regeneron
| Metric | CORT | REGN |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.64 |
| Last 12-Month Dividend Yield | N/A | 0.46% |
| 3-Year Avg Annual Dividend | N/A | $0.88 |
| 3-Year Avg Dividend Yield | N/A | 0.14% |
| 3-Year Total Dividends | N/A | $2.64 |
| Ex-Dividend Date | N/A | Aug 18, 2025 |